BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35559232)

  • 1. The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis.
    Wang L; Yin H; Yang L; Zhang F; Wang S; Liao D
    Front Pharmacol; 2022; 13():779694. PubMed ID: 35559232
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
    Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
    Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
    Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
    Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients.
    Lei J; Li H; Wang S
    Biomed Res Int; 2022; 2022():2413176. PubMed ID: 36420092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat.
    Tang M; Zhu C; Yan T; Zhou Y; Lv Q; Chuan J
    Front Pharmacol; 2021; 12():658079. PubMed ID: 34276361
    [No Abstract]   [Full Text] [Related]  

  • 6. The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials.
    Abdelazeem B; Abbas KS; Shehata J; El-Shahat NA; Baral N; Savarapu P; Kunadi A
    Ann Transl Med; 2021 Dec; 9(23):1714. PubMed ID: 35071408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
    Jia L; Dong X; Yang J; Jia R; Zhang H
    Ann Transl Med; 2019 Dec; 7(23):720. PubMed ID: 32042736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Malik B; Savarapu P; Eltobgy M; Kunadi A
    PLoS One; 2022; 17(4):e0266243. PubMed ID: 35363823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis.
    Hou YP; Wang C; Mao XY; Zhang MZ; Li B
    J Formos Med Assoc; 2022 Nov; 121(11):2288-2299. PubMed ID: 35871036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.
    Liu C; Fu Z; Jiang J; Chi K; Geng X; Mao Z; Song C; Sun G; Hong Q; Cai G; Chen X; Sun X
    Front Med (Lausanne); 2021; 8():724456. PubMed ID: 34532333
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials.
    Chen T; Huang J; Dong H; Xu L; Chen C; Tang Y; Huang W
    Front Nutr; 2022; 9():1029432. PubMed ID: 36466382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.
    Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S
    Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis.
    Chong S; Xie Q; Ma T; Xiang Q; Zhou Y; Cui Y
    Front Pharmacol; 2022; 13():967532. PubMed ID: 36188528
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness and safety of roxadustat in the treatment of anemia of kidney disease: a systematic review and meta-analysis.
    Wang H; Huang K; Wang C; Chen C; Fang H; Cao J
    Ann Palliat Med; 2021 Apr; 10(4):4736-4746. PubMed ID: 33966423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
    Zhou Q; Mao M; Li J; Deng F
    Ren Fail; 2023 Dec; 45(1):2195011. PubMed ID: 37489561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
    Zhang S; Guo J; Xie S; Chen J; Yu S; Yu Y
    Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
    Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
    Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review.
    Qie S; Jiao N; Duan K; Li J; Liu Y; Liu G
    Int Urol Nephrol; 2021 May; 53(5):985-997. PubMed ID: 33389461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.